Eloxx Pharmaceuticals, Inc. announced that it has hired a highly experienced ophthalmology executive, Dr. Susan Schneider, as Senior Vice President Ophthalmology to lead the clinical development team and will be responsible for strategic clinical oversight and the advancement of inherited retinal disease programs across library of eukaryotic ribosomal selective glycosides (ERSG). Dr. Schneider has extensive experience leading the clinical development and strategic planning efforts across a range of ocular indications at leading companies including most recently as Chief Medical Officer at ThromboGenics, Vice President and Therapeutic Head, Glaucoma & Retina, Glaucoma and wet AMD at Allergan, as well as leadership roles in Ophthalmology at GlaxoSmithKline, Bausch & Lomb, and Genentech.